A fully-loaded product pipeline in various stages of clinical development, Nobel Prize-winning advisors, partnerships with the University of Oxford and Yale University — and much more. At the heart of each one of our initiatives is a commitment to rigorous scientific research.
Our current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. Beyond Basis, Matter, Format, Signal, Mosaic, and Index, we are working with our scientific advisors and university partners to identify promising new research and innovative compounds.
These compounds are all tested for safety and efficacy in placebo-controlled human trials before coming to market.
As you can see from our preclinical studies and clinical trials outlined below, there’s a lot happening behind the scenes at Elysium — and a lot to look forward to.
Brain Vascular Health
Non-Alcoholic Fatty Liver (NAFL)
Muscle Injury and Repair
Acute Kidney Injury (AKI) Phase I
Acute Kidney Injury (AKI) Phase II
Repeat Dose Basis
EH301 for ALS
Partnership with the University of Oxford
Matter, our breakthrough product clinically proven to slow age-related brain atrophy, was developed in partnership with the University of Oxford and world-renowned scientist A. David Smith, Ph.D., Professor Emeritus of Pharmacology at the University of Oxford, Founding Director of OPTIMA, and Elysium Scientific Advisory Board member.
The Oxford-Elysium Fellowship Program
Elysium has established the Oxford-Elysium Fellowship program at the University of Oxford, which recruits the best researchers to work in cutting-edge laboratories.
The first fellow, Hanlin Zhang, discovered a new pathway for autophagy induction. Zhang works in the lab of Katja Simon, Professor of Immunology in the Kennedy Institute of Rheumatology in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences. Elysium owns first rights to all intellectual property developed by the fellow.
The second fellow, Adam Rolt, works in the lab of Lynne Cox at the University of Oxford’s Cox Lab of Ageing and Cell Senescence. Cox’s lab focuses on the genes and biochemical pathways that influence health outcomes in aging and promote healthy aging by treating age-related diseases at the cause.
Lewis Taylor is the third fellow in the Oxford-Elysium program, and works in Aarti Jagannath’s lab at the Nuffield Department of Clinical Neuroscience. Taylor’s focus is on researching the relationship between circadian rhythms, chronic disease, and biological age.
For further details on the Oxford-Elysium program and how to apply for fellowship, read more.
Partnership With Yale University
Elysium partnered with Morgan Levine, Ph.D., of Yale University and a leading researcher in the field of epigenetic predictors of age to develop Index, our revolutionary at-home epigenetic test.
Elysium Scholars: Helping Students Study Science
Elysium’s scholarship program is designed to encourage and assist students pursuing an education in science-related fields. There are currently six students enrolled in an undergraduate degree in a scientific field benefiting from the scholarship.
“Through Elysium Health's products and research focus on human health, the Elysium Scholars program takes an expansive approach to science. We believe that encouraging young people to pursue a career in any scientific field is a critical step toward future breakthroughs and innovations that may have a meaningful impact on the overall health of our society." - Elysium co-founder and chief scientist Leonard Guarente, Ph.D.